GlassScriptPhysician profile
Sujala Chirla
NPI 1790946663
$1,877.70
in general payments reported to CMS, 2019-2025
21 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2021: $177 · 2022: $59.12 · 2023: $356 · 2024: $785 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $495.18 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $335.28 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Pfizer INC. | $187.07 | 2023-2025 | |
| Olympus America INC. | $115.19 | 2019-2023 | Evis Exera Lll Colonovideoscope |
| Pharmacosmos Therapeutics INC. | $108.53 | 2024 | Monoferric |
| Janssen Biotech, INC. | $107.99 | 2022-2025 | Tremfya |
| Gilead Sciences, INC. | $77.01 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $59.36 | 2023-2025 | Ocaliva |
| Lilly USA, LLC | $57.00 | 2024 | Omvoh |
| Ardelyx, INC. | $47.37 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $42.54 | 2023 | Rebyota |
| Celgene Corporation | $42.10 | 2021-2024 | Zeposia |
| Vivus LLC | $32.40 | 2024-2025 | Pancreaze, Qsymia |
| Merck Sharp & Dohme LLC | $30.55 | 2022-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $30.04 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $28.31 | 2022-2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $18.56 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $17.68 | 2025 | Rezdiffra |
| Celltrion USA INC. | $16.47 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $15.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.89 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujala Chirla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.